Tag: Mydecine - Psychedelic Alpha

Our 2022 Year in Review is now live.

Read more about the article MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Post published:January 20, 2023
Post category:Press Release

Read more about the article Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.

Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.

Post published:December 12, 2022
Post category:Press Release

Read more about the article MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Post published:December 9, 2022
Post category:Press Release

Read more about the article MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES NEW CFO

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES NEW CFO

Post published:September 24, 2022
Post category:Press Release

Read more about the article MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Post published:September 15, 2022
Post category:Press Release

Read more about the article MYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORS

MYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORS

Post published:August 12, 2022
Post category:Press Release

Read more about the article Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

Post published:July 20, 2022
Post category:Press Release

Read more about the article U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Post published:June 17, 2022
Post category:Press Release

Read more about the article Mydecine Announces Reverse Stock-Split

Mydecine Announces Reverse Stock-Split

Post published:April 13, 2022
Post category:Press Release

Read more about the article Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update

Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update

Post published:April 1, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.